| Sign In to gain access to subscriptions and/or personal tools. |
Pattern of ziprasidone exposures reported to Texas poison centers, 2001–2005Epidemiology and Surveillance Unit, Texas Department of State Health Services, Austin, Texas, USA mathias.forrester{at}dshs.state.tx.us
Information on potentially adverse exposures to the atypical antipsychotic drug ziprasidone is limited. This study described the pattern of exposures involving only ziprasidone (isolated exposures) reported to Texas poison control centers during 2001–2005. The mean dose was 666 mg. The patient age distribution was
Key Words: adverse exposures • antipsychotic • poison control centers • ziprasidone
Human & Experimental Toxicology, Vol. 27, No. 4,
355-361 (2008) |
||||
 |
|
|
 |
Sign In to gain access to subscriptions and/or personal tools.
5 years (11%), 6–19 years (30%), and 
20 years (60%). The exposures were intentional in 53% of the cases. Seventy-five percent of the exposures were managed at health care facilities. The final medical outcome was classified as no effect for 39% of the cases and minor effects for 40% of the cases. Adverse clinical effects were listed for 53% of the patients; the most frequently reported being neurological (42%), cardiovascular (13%), and gastrointestinal (5%). The most frequently listed treatment was decontamination by charcoal (34%) or cathartic (28%). Potentially adverse ziprasidone exposures reported to poison control centers are likely to involve management at a health care facility and involve some sort of adverse clinical effect. With proper treatment, the outcomes of such exposures are generally favorable.